RGNX (REGENXBIO Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by RGNX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-04 | STEVE PAKOLA | Chief Medical Officer | F | — | — |
| 2026-08-04 | Patrick J. Christmas | Chief Strategy & Legal Officer | F | — | — |
| 2026-07-06 | Curran Simpson | Chief Executive Officer | MIXED | — | — |
| 2026-07-06 | STEVE PAKOLA | Chief Medical Officer | MIXED | — | — |
| 2026-07-01 | STEVE PAKOLA | Chief Medical Officer | MIXED | — | — |
| 2026-06-02 | Daniel Tasse | Director | A | — | — |
| 2026-06-02 | DAVID C STUMP | Director | A | — | — |
| 2026-06-02 | ARGERIS N KARABELAS | Director | A | — | — |
| 2026-06-02 | Allan M. Fox | Director | A | — | — |
| 2026-06-02 | GEORGE V MIGAUSKY | Director | A | — | — |
| 2026-06-02 | Kenneth T. Mills | Director | A | — | — |
| 2026-06-02 | Alexandra Glucksmann | Director | A | — | — |
| 2026-06-02 | Jennifer Zachary | Director | A | — | — |
| 2026-06-02 | Jean Bennett | Director | A | — | — |
| 2026-05-13 | STEVE PAKOLA | Chief Medical Officer | Sell | — | — |
| 2026-03-12 | STEVE PAKOLA | Chief Medical Officer | Sell | — | — |
| 2026-02-03 | Patrick J. Christmas | Chief Strategy & Legal Officer | F | — | — |
| 2026-02-03 | STEVE PAKOLA | Chief Medical Officer | F | — | — |
| 2026-01-29 | Kenneth T. Mills | Director | MIXED | — | — |
| 2026-01-08 | Curran Simpson | Chief Executive Officer | A | — | — |
| 2026-01-08 | Patrick J. Christmas | Chief Strategy & Legal Officer | A | — | — |
| 2026-01-08 | Craig Malzahn | Chief Technology Officer | A | — | — |
| 2026-01-08 | STEVE PAKOLA | Chief Medical Officer | A | — | — |
| 2026-01-08 | Mitchell Chan | Chief Financial Officer | A | — | — |
| 2026-01-06 | Patrick J. Christmas | Chief Strategy & Legal Officer | F | — | — |
| 2026-01-06 | STEVE PAKOLA | Chief Medical Officer | F | — | — |
| 2026-01-06 | Craig Malzahn | Chief Technology Officer | F | — | — |
| 2026-01-06 | Curran Simpson | Chief Executive Officer | F | — | — |
| 2025-10-10 | Curran Simpson | Chief Executive Officer | Sell | — | — |
| 2025-10-01 | Curran Simpson | Chief Executive Officer | Sell | — | — |
| 2025-09-12 | Curran Simpson | Chief Executive Officer | Sell | — | — |
| 2025-09-03 | Craig Malzahn | Chief Technology Officer | F | — | — |
| 2025-09-03 | Mitchell Chan | Chief Financial Officer | F | — | — |
| 2025-08-04 | Patrick J. Christmas | Chief Strategy & Legal Officer | F | — | — |
| 2025-07-03 | Curran Simpson | Chief Executive Officer | F | — | — |
| 2025-06-03 | Daniel Tasse | Director | A | — | — |
| 2025-06-03 | Jennifer Zachary | Director | A | — | — |
| 2025-06-03 | DAVID C STUMP | Director | A | — | — |
| 2025-06-03 | Jean Bennett | Director | A | — | — |
| 2025-06-03 | GEORGE V MIGAUSKY | Director | A | — | — |
| 2025-06-03 | Alexandra Glucksmann | Director | A | — | — |
| 2025-06-03 | Allan M. Fox | Director | A | — | — |
| 2025-06-03 | ARGERIS N KARABELAS | Director | A | — | — |
| 2025-06-03 | Kenneth T. Mills | Director | A | — | — |
| 2025-05-14 | Kenneth T. Mills | Director | MIXED | — | — |
| 2025-04-04 | Patrick J. Christmas | Chief Legal Officer | F | — | — |
| 2025-04-04 | Olivier Danos | Chief Scientific Officer | F | — | — |
| 2025-04-04 | STEVE PAKOLA | Chief Medical Officer | F | — | — |
| 2025-03-31 | Kenneth T. Mills | Director | M | — | — |
| 2025-01-14 | Curran Simpson | Chief Executive Officer | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 1,169,042 | — |
| — | Director | 751,346 | — |
| — | 10%+ Owner | 619,376 | — |
| — | Director | 495,925 | — |
| — | Chief Executive Officer | 343,418 | — |
| — | Chief Financial Officer | 246,534 | — |
| — | Chief Scientific Officer | 226,348 | — |
| — | Chief Strategy & Legal Officer | 205,968 | — |
| — | Chief Medical Officer | 205,541 | — |
| — | Chief Financial Officer | 127,717 | — |
| — | Director | 114,108 | — |
| — | Chief Technology Officer | 82,194 | — |
| — | Director | 31,871 | — |
| — | Director | 28,861 | — |
| — | Director | 28,861 | — |
| — | Director | 28,861 | — |
| — | Director | 28,861 | — |
| — | Director | 28,861 | — |
| — | Director | 28,861 | — |
| — | Director | 12,784 | — |
| — | Chief Medical Officer | 507 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the RGNX quote page; the site-wide leaderboard is on the insider transactions hub.